View details of this raise on Seedstage

Fremont, CA

Developing a rapid radiotherapy platform to improve cancer treatment outcomes.

• Innovative Technology: TibaRay’s FLASH radiotherapy delivers treatment over 400 times faster than current methods.
• Robust IP Portfolio: The company holds over 20 issued and pending patents on its radiotherapy technology.
• Strategic Partnerships: Partnerships with technology providers integrate TibaRay’s core technology into treatment systems.
• Market Potential: The global radiotherapy market is valued at $9 billion, with additional applications in other medical fields.
• State-of-the-Art Facility: TibaRay operates a 24,000 sq ft facility for prototyping, testing, and production in Silicon Valley.

TibaRay is developing an advanced radiotherapy platform designed to enhance cancer treatment outcomes while minimizing side effects, costs, and treatment duration. The company’s technology, known as FLASH, delivers radiation therapy in a fraction of a second, significantly faster than current methods. This rapid delivery can reduce damage to healthy tissues, allowing for more effective treatments. TibaRay’s innovations in accelerator physics and beam control make FLASH clinically feasible, offering a promising advancement in cancer care.

The company operates a fully integrated facility in Silicon Valley, equipped for prototyping, testing, and production. TibaRay’s technology is backed by a robust intellectual property portfolio, including over 20 patents. The company has formed strategic partnerships to integrate its technology into existing treatment systems. With a focus on the $9 billion global radiotherapy market, TibaRay aims to expand its applications to other medical conditions, such as cardiac arrhythmias and pulmonary emphysema. The company’s long-term goal is to commercialize its PHASER system, leveraging proprietary technology to address large global markets.

Company Info

TibaRay is developing a rapid radiotherapy platform to enhance cancer treatment efficacy and safety.

TibaRay is focused on developing an advanced radiotherapy platform designed to improve cancer treatment outcomes. The company is pioneering the use of FLASH radiotherapy, which delivers radiation treatment in a fraction of a second, significantly faster than current technologies. This approach aims to reduce damage to healthy tissues, allowing for more effective and curative treatments. TibaRay’s technology is based on innovations in accelerator physics and RF systems, making conformal FLASH clinically feasible for the first time.

The company operates a fully integrated facility in Silicon Valley, equipped for prototyping, testing, and production. TibaRay’s business model includes delivering linear accelerators for various applications, including healthcare and non-destructive testing, with a long-term goal of commercializing the PHASER system. The global radiotherapy market presents significant opportunities, and TibaRay aims to leverage its proprietary technology to address these markets effectively.